Tuberculosis in the Bajo Deba Area (Guipúzcoa, Spain) from 1995 to 2006;Tuberculosis en la comarca del Bajo Deba (Guipúzcoa) en el período 1995-2006

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 4, 2008, Pages 187-193

  García Zamalloa, Alberto Ma ^a   Arrizabalaga, Julio ^b  

^a HOSPITAL DE MENDARO   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

Author keywords

Epidemiology; HIV; Resistance; Tuberculosis

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INCIDENCE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; SPAIN; TUBERCULOSIS;

EID: 42149118399     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)72689-2     Document Type: Article

References (30)

1. Dye C, Watt CJ, Bleed DM, Mosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence and deaths globally. JAMA. 2005;293:2767-75.
2. Dye CD, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. JAMA. 1999;282:677-86.
3. Grupo de Trabajo del Proyecto Multicéntrico de Investigación sobre Tuberculosis. La tuberculosis en España: resultados del Proyecto Multicéntrico de Investigación sobre Tuberculosis (PMIT). Editor: Instituto de Salud Carlos III, Madrid 1999.
4. Light RW. Establishing the diagnosis of tuberculous pleuritis. Arch Intern Med. 1998;158:1967-8.
5. ATS/CDC/IDSA Document. Treatment of tuberculosis: principles of antituberculous chemotherapy and recommended treatment regimens. Am J Respir Crit Care Med. 2003;167:629-34.
6. Bajo Deba-Deba Beherea. Informe técnico. Servicio de Planificación y Ordenación Territorial. Diputación Provincial de Guipúzcoa. San Sebastián 1998;p. 31-44.
7. Raviglione MC, Snider DE, Arata K. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA. 1995;273:220-6.
8. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-21.
9. Cegielski JP, Chin DP, Espinal MA, Frieden TR, Rodríguez-Cruz R, Talbot EA, et al. The global tuberculosis situation: Progress and problems in the 20th century, prospects for the 21th century. Infect Dis Clin North Am. 2002;16:1-58.
10. Raviglione MC. The TB epidemic from 1992 to 2002. Tuberculosis. 2003;83:4-14.
11. Caminero JA. Medidas básicas para el control de la tuberculosis en una comunidad. Med Clin (Barc). 1994;102:67-73.
12. Caminero JA. Tuberculosis en el paciente anciano. An Med Intern. 1997;14:163-6.
13. Fine P, Small P. Exogenous reinfection in tuberculosis. N Engl J Med. 1999;341:1226-7.
14. Surendra KS, Alladi M, Anju S, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis. 2005;5:415-30.
15. Rodríguez LC, Diwan WK, Wheeler JG. Protective effect of BCG against tuberculosis meningitis and military tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22:1154-8.
16. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, et al. Long-term efficacy of BCG vaccine in American indians and Alaska natives: a 60-yer follow-up study. JAMA. 2004;291:2086-91.
17. Soysal A, Millington K, Bakir M, Dosanjh D, Aslan Y, Deeks J, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet. 2005;366:1443-51.
18. Bourdin Trunz B, Fine PEM, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and military tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173-80.
19. Teo SS, Shingadia DV. Does BCG have a role in tuberculosis control and prevention in the United Kingdom? Arch Dis Child. 2006;91:529-31.
20. Executive Committee and Council of the IUATLD. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guérin (BCG) in countries with a low prevalence of tuberculosis. Tuber Lung Dis. 1994;75:179-81.
21. Pérez-Trallero E. Tuberculosis. España es diferente y el olvido del BCG. An Pediatr (Barc). 2006;64:1-4.
22. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the Quantiferon-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR. 2005;54(RR-15):49-55.
23. Pai M, Riley LW, Coldfor JM. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761-76.
24. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-50.
25. Shafer RW, Edlin BR. Tuberculosis in patients infected with Human Immunodeficiency Virus: perspective of the past decade. Clin Infect Dis. 1996;22:683-704.
26. Martín V, Caylá JA, Bolea A, Castilla J. Mycobacterium tuberculosis and human immunodeficiency virus coinfection in intravenous drug users on admision to prison. Int J Tuberc Lung Dis. 2000;4:41-6.
27. Zumla A, Malon P, Henderson J, Grange JM. Impact of VIH infection on tuberculosis. Posgrad Med J. 2000;76:259-68.
28. Bleed D, Dye C, Raviglione MC. Dynamics and control of the global tuberculosis epidemic. Curr Opin Pulm Med. 2000;6:174-9.
29. Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med. 2001;345:189-200.
30. Díez Ruiz-Navarro M, Hernández Espinosa JA, Caloto González T, Castells Carrillo C, Domínguez García A, García Fulgueiras AM, et al, por el Grupo de Trabajo del PMIT-2. Resultado del tratamiento antituberculoso en seis comunidades autónomas españolas. Med Clin (Barc). 2001;117:474-80.